Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Dysbiosis of the Gut Microbiota

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...

Inflammatory Bowel Disease I: Introduction

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Lei et al. The Diagnostic Accuracy of Colon Capsule Endoscopy in Inflammatory Bowel Disease-A Systematic Review and Meta-Analysis. <i>Diagnostics</i> 2024, <i>14</i>, 2056.

Diagnostics (Basel, Switzerland)·2025

Same author

Comment on Altobelli et al. Colon Capsule Endoscopy as a Promising Diagnostic Tool in Colorectal Cancer: A Systematic Review and Network Meta-Analysis. <i>Diagnostics</i> 2025, <i>15</i>, 2157.

Diagnostics (Basel, Switzerland)·2025

Same author

Red cells, red flags: are we harming stable patients with outdated transfusion thresholds?

Gut·2025

Same author

Retrospective review of CO<sub>2</sub> laser pre-treatment photodynamic therapy for basal cell carcinoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

Cost of reusable gastrointestinal endoscopes to the NHS: findings from a micro-costing study.

BMJ open gastroenterology·2025

Same author

Steroid-Resistant Rash With Neuropsychiatric Deterioration and Weight Loss: A Modern-Day Case of Pellagra.

Cureus·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments.

Naveen Sivakumar¹, Ashwin Krishnamoorthy², Harshita Ryali³

¹Institute of Precision Diagnostics & Translational Medicine, University Hospitals Coventry & Warwickshire, Coventry CV2 2DX, UK.

|March 28, 2025

Summary

Novel non-surgical treatments for inflammatory bowel disease (IBD) show promise. Research in the gut microbiome and gene therapy offers potential for safer, targeted therapies in human trials.

Keywords:

faecal transplantation gene therapy inflammatory bowel disease microbiome microbiota nanoparticle

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

Related Experiment Videos

Last Updated: Jun 21, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

Area of Science:

Gastroenterology and Immunology
Translational Medicine

Background:

Inflammatory bowel disease (IBD) management often involves surgery as a last resort, carrying significant risks.
Emerging therapies aim to modulate the host immune response in IBD patients.

Purpose of the Study:

To review novel, non-surgical treatments for IBD published between March 2024 and February 2025.
Focus on advancements in gut microbiome and gene therapy for IBD.

Main Methods:

Literature review of IBD treatments from March 2024 to February 2025.
Emphasis on research concerning the gut microbiome and gene therapy applications.

Main Results:

Novel therapies are increasing in safety and popularity.
Animal studies demonstrate promising results for probiotic therapies, with potential for human trials post-FDA approval.
Targeted anti-inflammatory approaches show efficacy in preclinical models.

Conclusions:

Promising diagnostics and novel therapies are emerging for IBD.
Preclinical research indicates safe and transferable therapeutic strategies for specific inflammation sites.
Immune response modulation presents a viable and safe therapeutic avenue for future IBD research.